Literature DB >> 26160475

Genetic polymorphisms and oxidative stress in non-alcoholic steatohepatitis (NASH): A mini review.

Claudia P Oliveira1, Jose Tadeu Stefano2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common form of liver disease, thus becoming an epidemic in the Western world with a major impact on public health. NAFLD encompasses a large spectrum of disease ranging from simple steatosis to non-alcoholic steatohepatitis (NASH) and may progress to fibrosis, cirrhosis and hepatocellular carcinoma (HCC). The role of genetic polymorphisms is not clear. Evidence supports the hypothesis that genetic factors are involved in the predisposition to NAFLD, and thus should emphasize the polygenic nature of the disease as a limiting factor in these studies. However, the polymorphic allele associated with increased hepatic steatosis appears to be associated with various different combinations of phenotypes, including increase or decrease of the biochemical and clinical parameters. It is possible that SNPs in genes involved in excessive fatty acid oxidation would predispose to NASH. On the other hand, the SNPs could determine the inadequate mitochondrial overload during times of excessive FFA supply. However due to the multiple hits involving some pathways, a brief review of genetic variants on mediators of oxidative stress, inflammation and lipid metabolism pathways is presented. It is clear that the discovery of genetic and environmental associations, robust enough to direct the treatment and to trace specific prevention strategies would only be possible with studies examining the susceptibility of NAFLD in a number of individuals considerably higher than assessed so far. These studies need a large number of well phenotyped cases and controls and certainly require national and international collaboration.
Copyright © 2015 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26160475     DOI: 10.1016/j.clinre.2015.05.014

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  9 in total

Review 1.  Is That Possible to Stop or Cease the NASH to Turn into HCC?

Authors:  Ahmet Uygun
Journal:  J Gastrointest Cancer       Date:  2017-09

2.  Major Components of Metabolic Parameters and Nutritional Intakes in Different Genotypes of Adiponectin +276 G>T Gene Polymorphism in Non-Diabetes and Non-Alcoholic Iranian Fatty Liver Patients.

Authors:  Fatemeh Mohseni; Sahar Moghbelinejad; Reza Najafipour
Journal:  Avicenna J Med Biotechnol       Date:  2017 Jul-Sep

3.  The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α.

Authors:  Tingting Ren; Juanjuan Zhu; Lili Zhu; Mingliang Cheng
Journal:  Nutrients       Date:  2017-02-27       Impact factor: 5.717

4.  Current and emerging pharmacological therapy for non-alcoholic fatty liver disease.

Authors:  Ahad Eshraghian
Journal:  World J Gastroenterol       Date:  2017-11-14       Impact factor: 5.742

5.  Genomics of lipid-laden human hepatocyte cultures enables drug target screening for the treatment of non-alcoholic fatty liver disease.

Authors:  Stephanie Breher-Esch; Nishika Sahini; Anna Trincone; Christin Wallstab; Jürgen Borlak
Journal:  BMC Med Genomics       Date:  2018-12-14       Impact factor: 3.063

Review 6.  The Natural Course of Non-Alcoholic Fatty Liver Disease.

Authors:  Luis Calzadilla Bertot; Leon Anton Adams
Journal:  Int J Mol Sci       Date:  2016-05-20       Impact factor: 5.923

7.  Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients.

Authors:  Julia Uhanova; Gerald Minuk; Federico Lopez Ficher; Natasha Chandok
Journal:  Can J Gastroenterol Hepatol       Date:  2016-04-28

8.  Non-alcoholic steatohepatitis-related liver tumorigenesis is suppressed in mice lacking hepatic retinoid storage.

Authors:  Takayasu Ideta; Yohei Shirakami; Masaya Ohnishi; Akinori Maruta; Koki Obara; Tsuneyuki Miyazaki; Takahiro Kochi; Hiroyasu Sakai; Hiroyuki Tomita; Takuji Tanaka; William S Blaner; Masahito Shimizu
Journal:  Oncotarget       Date:  2017-08-07

9.  Differentially methylated loci in NAFLD cirrhosis are associated with key signaling pathways.

Authors:  Glenn S Gerhard; Ivana Malenica; Lorida Llaci; Xin Chu; Anthony T Petrick; Christopher D Still; Johanna K DiStefano
Journal:  Clin Epigenetics       Date:  2018-07-13       Impact factor: 6.551

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.